Treatment of pSTAT3 DLBCL cells with the HDAC inhibitor panobinostat (LBH589) increased p300/CBP-mediated STAT3 Lys685 acetylation and abolished STAT3 Tyr705 phosphorylation with a negligible effect on STAT3 Ser727 and JAK2 tyrosine activity [59]. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.